New Alanine Racemase Inhibitors Found to Fight Tuberculosis
Author Information
Author(s): Karen G. Anthony, Ulrich Strych, Kacheong R. Yeung, Carolyn S. Shoen, Oriana Perez, Kurt L. Krause, Michael H. Cynamon, Paul A. Aristoff, Raymond A. Koski
Primary Institution: L2 Diagnostics, LLC
Hypothesis
Can high-throughput screening identify novel non-substrate inhibitors of alanine racemase that are effective against Mycobacterium tuberculosis?
Conclusion
The study successfully identified several novel alanine racemase inhibitors that show antimicrobial activity against Mycobacterium tuberculosis with low cytotoxicity.
Supporting Evidence
- Seventeen novel non-substrate alanine racemase inhibitors were identified.
- Seven of these inhibitors showed activity against Mycobacterium tuberculosis.
- The inhibitors demonstrated minimal cytotoxicity against mammalian cells.
Takeaway
Researchers looked for new medicines to fight tuberculosis by testing a lot of different chemicals, and they found some that work well without hurting healthy cells.
Methodology
High-throughput screening of 53,000 small molecule compounds was conducted to identify non-substrate alanine racemase inhibitors.
Limitations
The study primarily focused on in vitro results, and further in vivo studies are needed to confirm the efficacy and safety of the identified inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website